This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 137 words of the full text and any section headings.

Participants of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) continue to write descriptive articles that omit the information on the dose of the drug used.¹ This is especially important in the case of renal disease, for which the issue of the effectiveness of an angiotensin-converting enzyme inhibitor is addressed. The study design allowed the use of as little as 10 mg of lisinopril, which is too low a dose for efficacy. Many readers would like to know whether 3% of the patients were receiving 10 mg of lisinopril or 30% or more than half. Did the dose influence the outcome? We will have to reserve judgment on the meaning of the data until that information is available.

AUTHOR INFORMATION
Correspondence: Dr Hollenberg, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115 (djpagecapo@rics.bwh.harvard.edu).

Norman K. Hollenberg, MD, PhD

1. Rahman M, Pressel S, Davis BR, et al, ALLHAT Collaborative Research Group. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936-946. FREE FULL TEXT

Arch Intern Med. 2006;166:368.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Omission of Drug Dose Information—Reply
Mahboob Rahman, Sara L. Pressel, and Barry R. Davis
Arch Intern Med. 2006;166(3):368-369.
EXTRACT | FULL TEXT  

Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Mahboob Rahman, Sara Pressel, Barry R. Davis, Chuke Nwachuku, Jackson T. Wright, Jr, Paul K. Whelton, Joshua Barzilay, Vecihi Batuman, John H. Eckfeldt, Michael Farber, Mario Henriquez, Nelson Kopyt, Gail T. Louis, Mohammad Saklayen, Carol Stanford, Candace Walworth, Harry Ward, Thomas Wiegmann, and for the ALLHAT Collaborative Research Group
Arch Intern Med. 2005;165(8):936-946.
ABSTRACT | FULL TEXT